Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Volition: Edison Open House Healthcare 2022

Volition: Edison Open House Healthcare 2022

VolitionRx Limited manufactures epigenetic cancer detection blood tests. The Company’s tests are designed to detect the nucleosome patterns that are specific to cancer in the blood and identify some of the major nucleosome varieties that differ between cancer types.

• Please provide a summary of nucleosomes.
• Please explain how you look for disease through supplementary information found in the nucleosomes?
• How will Volition commercialise this platform?
• What kind of disease is detected? Is it in humans and dogs?
• Is this process used for screening or diagnosis?
• In 2021, you made the shift from an R&D-focused company to a commercial company. How have you added to your team to support this?
• Please tell us about your Nu.Q. platform.
• Are you continuing to run R&D alongside your commercialisation work?
• What are your key priorities for 2022?

< Previous
Next >

You may also be interested in these:

Consumer

Unlocking London’s hidden tunnels: Investing in a major underground tourist attraction
sharesoc pic

Investment Companies

ShareSoc webinar – The Biotech Growth Trust

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free